Clinical Trials · NCT07226778

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

Name: Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Maridebart cafraglutide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Amgen
Enrollment: 348
Start date: Oct 2025
Locations: 4 sites, United States
Primary endpoint: Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUCinf) of Maridebart Cafraglutide

View Maridebart-Cafraglutide compound reference